Latest News
Kelun-Biotech publishes phase III data for trastuzumab botidotin in HER2-positive breast cancer
14 September 2026 - Chinese biopharmaceutical company Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) on Monday announced that it has published phase III results for its HER2-targeted antibody–drug conjugate trastuzumab botidotin ...
FDA grants priority review to Takeda's zasocitinib application for plaque psoriasis
14 September 2026 - Japanese pharmaceutical company Takeda (TSE:4502) (NYSE:TAK) said on Monday that the US Food and Drug Administration (FDA) has accepted its new drug application for zasocitinib (TAK-279) under Priority Review for adults with moder...
Armata Pharmaceuticals announces receipt of FDA Breakthrough Therapy Designation for AP-SA02
14 September 2026 - Biotechnology company Armata Pharmaceuticals Inc (NYSE American: ARMP) reported on Monday that it has received U.S. Food and Drug Administration Breakthrough Therapy designation for AP-SA02, its intravenous multi-phage product can...
AstraZeneca's Etcamah misses primary endpoint in Phase III breast cancer trial
14 September 2026 - Biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (NYSE:AZN) disclosed on Monday that its Phase III SERENA-4 trial of Etcamah (camizestrant) in combination with palbociclib did not achieve its primary endpoint of a sta...
GSK reports positive Jideytro data supporting potential first-line lung cancer use
14 September 2026 - Biopharmaceutical company GSK plc (LSE: GSK) (NYSE: GSK) on Monday reported positive registrational Phase I/II ARROS-1 data for Jideytro (zidesamtinib) in previously untreated ROS1-positive non-small cell lung cancer (NSCLC), supp...